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Prophylactic melatonin significantly reduces
Alzheimer’s neuropathology and associated
cognitive deficits independent of antioxidant
pathways in AβPPswe/PS1 mice
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Abstract
Background: Alzheimer’s disease (AD) underlies dementia for millions of people worldwide, and its occurrence is set
to double in the next 20 years. Currently, approved drugs for treating AD only marginally ameliorate cognitive deficits,
and provide limited symptomatic relief, while newer substances under therapeutic development are potentially years
away from benefiting patients. Melatonin (MEL) for insomnia has been proven safe with >15 years of over-the-counter
access in the US. MEL exerts multiple complementary mechanisms of action against AD in animal models; thus it may
be an excellent disease-modifying therapeutic. While presumed to provide neuroprotection via activation of known
G-protein-coupled melatonin receptors (MTNRs), some data indicate MEL acts intracellularly to protect mitochondria
and neurons by scavenging reactive oxygen species and reducing free radical formation. We examined whether
genetic deletion of MTNRs abolishes MEL’s neuroprotective actions in the AβPPswe/PSEN1dE9 mouse model of
AD (2xAD). Beginning at 4 months of age, both AD and control mice either with or without both MTNRs were
administered either MEL or vehicle in drinking water for 12 months.
Results: Behavioral and cognitive assessments of 15-month-old AD mice revealed receptor-dependent effects of MEL
on spatial learning and memory (Barnes maze, Morris Water Maze), but receptor-independent neuroprotective actions
of MEL on non-spatial cognitive performance (Novel Object Recognition Test). Similarly, amyloid plaque loads in
hippocampus and frontal cortex, as well as plasma Aβ1–42 levels, were significantly reduced by MEL in a receptor-
independent manner, in contrast to MEL’s efficacy in reducing cortical antioxidant gene expression (Catalase,
SOD1, Glutathione Peroxidase-1, Nrf2) only when receptors were present. Increased cytochrome c oxidase activity
was seen in 16mo AD mice as compared to non-AD control mice. This increase was completely prevented by
MEL treatment of 2xAD/MTNR+ mice, but only partially prevented in 2xAD/MTNR- mice, consistent with mixed
receptor-dependent and independent effects of MEL on this measure of mitochondrial function.
Conclusions: These findings demonstrate that prophylactic MEL significantly reduces AD neuropathology and
associated cognitive deficits in a manner that is independent of antioxidant pathways. Future identification of
direct molecular targets for MEL action in the brain should open new vistas for development of better AD
therapeutics.
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Background
Current therapeutics and drugs for improving memory
loss in Alzheimer’s disease (AD) patients only marginally
ameliorate cognitive deficits, and provide patients with
only restricted symptomatic relief [1–3]. Many com-
pounds under therapeutic development are years away
from benefiting AD patients. Thus, there is a critical
need for rapid development of safe, effective therapeutics
against AD. Melatonin analogs may provide such a
therapeutic.
Melatonin (MEL) is known to modulate many physio-
logical functions [4–6]. With advancing age and certain
age-related diseases, the endogenous secretion of MEL
drops markedly, and MEL supplementation can amelior-
ate sleep disorders in the aged [7]. Declines in blood and
CSF MEL levels in Alzheimer disease patients have been
reported to parallel the progression of neuropathology
[8, 9]. Although MEL has been given routinely to AD
patients to suppress sundowning, few publications have
investigated the cognitive effects of MEL administration
on AD patients. MEL stabilized cognitive function in
AD patients over a 2–3 year period [10] and improved
cognitive performance in mild cognitive impairment
(MCI) individuals [11]. A 3-year course of MEL treat-
ment to one of a pair of monozygotic AD twins resulted
in milder cognitive impairment for the treated twin [12].
Despite these epidemiologic and anecdotal reports, all of
which involved low MEL doses (≤9 mg/day), no con-
trolled clinical studies of MEL effects on cognition in
AD patients have been published. MEL is amphiphilic,
thus it is able to penetrate all cellular compartments and
freely enter the brain, especially from the CSF [13, 14].
The pharmacokinetics and oral bioavailability of
exogenously-administered MEL and analogs have been
well-established in preclinical and clinical studies [15].
Considerable in vitro evidence supports the premise
that MEL exerts an anti-amyloid-β (Aβ) aggregation ef-
fect [16–18]. MEL has been shown to protect against
Aβ-induced neurotoxicity in vitro and in vivo [17–22].
We and others have also demonstrated significantly re-
duced amyloid plaque burden in AD mice treated for
several months [23, 24]. Interestingly, the neuroprotec-
tion afforded by MEL in AD mice appears to be age-
dependent [25] in as much as treating mice from 4 to
8 months was not found to be significantly beneficial,
whereas MEL from 8 to 12 months of age (or from 4 to
12 months of age) significantly preserved cognition while
reducing amyloid plaque load in these animals. In an-
other study [26], a very low dose of MEL (0.08 mg/day)
was administered to aged Tg2576 (APPswe) mice begin-
ning at 14–18 months of age. Neither soluble Aβ levels
nor Aβ deposition was affected in cortex, leading the au-
thors to conclude that MEL is unlikely to be a treatment
for already established AD. However, the low dose of
MEL utilized in their study, the very late onset of
treatment, the lack of cognitive evaluation, and non-
assessment of any other key markers, are clearly in con-
trast to our previous studies and the present study.
MEL has often been reported to have anti-inflammatory
(and occasionally pro-inflammatory) properties in many
species, including humans [27–29]. It is noteworthy
that MEL administration lessens Aβ-induced pro-
inflammatory cytokine levels in rat and mouse brains
[23, 30]. Indeed, MEL may represent a new class of
anti-inflammatory agent [31], with accumulating evi-
dence for a significant role in reducing neuroinflamma-
tion via diverse mechanisms (Hardeland et. 2015 ibid).
Melatonin offers neuroprotection at the level of mito-
chondrial function [32, 33]. Consistent with this idea,
our published work points to reduced oxidative stress
in a mouse model of AD (AβPPswe/PSEN1dE9) after ad-
ministration of MEL for ≥ 1 month [23, 33] and a MEL-
mediated decrease in COX activity in the striatum of
our double AD mice. Finally, evidence demonstrates
that MEL can decrease tau hyperphosphorylation in cell
cultures [34]. Another mechanism through which MEL
may protect against cognitive impairment is through
stabilization and enhancement of dendritic structure.
Prior studies have shown that MEL is capable of
preventing loss of dendritic length and number for pre-
frontal cortical neurons of rats subjected to global
ischemia [35–37]. MEL has also been reported to pro-
mote dendritogenesis in the hippocampus [38]. Thus,
MEL appears to exert multiple complementary mecha-
nisms of action in the brain and hence may be an excel-
lent therapeutic against AD.
Despite these consistent and significant actions of
MEL on the cognition and pathology of the AD mouse
brain, the mechanisms of MEL action remain unclear. In
two recent reports [39, 40] the cognitive function of
transgenic AD mice was assessed after treatment with
the specific, nonselective MTNR ligand, Ramelteon®
(Takeda Pharmaceuticals), for up to 6 months. Ramelteon®
is a commercially available, clinically tested (for insomnia),
highly specific agonist at both MTNRs, having no direct
intracellular activity [41]. Intriguingly, and despite evi-
dence for reduced hippocampal protein oxidation [40],
Ramelteon® in these two studies was ineffective in lower-
ing amyloid plaque load or preserving cognitive functions.
The most parsimonious interpretation of these findings is
that MEL acts via MTNR-independent mechanisms to
cognitively protect the amyloid-afflicted brain.
In an effort to provide clarity on this matter, we have
generated transgenic AβPPswe/ PSEN1dE9 (2xAD) mice
that lack both known MTNRs (MTNR-) in order to de-
termine whether MEL has neuroprotective capabilities
that are independent of these receptors. Cognitive per-
formance, Aβ hippocampal plaque load, blood Aβ1–40
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and Aβ1–42 levels, and key markers of brain oxidative
stress were assessed in 2xAD mice with or without
MTNRs that received long-term MEL. Compared to
NonAD mice, the 2xAD animals developed significant
cognitive deficits that were lessened by MEL. In some
cognitive domains this neuroprotection was seen even in
the absence of MTNRs. Similarly, amyloid plaque load
in the hippocampus and frontal cortex as well as circu-
lating levels of Aβ1–42 were significantly lowered by
MEL in an MTNR-independent manner. These results
strongly suggest that MEL provides neuroprotective ef-
fects in the AD brain in a manner that is to some degree
independent of the two known membrane receptors.
Results
Behavioral testing
Sensorimotor and locomotor behavior
No evidence of sensorimotor deficits was seen on the
Platform Recognition or Rota-rod tests at any of the ages
tested (Fig. 1). There were no statistical differences be-
tween groups, trials or the interaction in the Platform
Recognition test and no significant differences (p > 0.05)
on Rota-rod performance between the two genotypes at
any age. It is worth noting that these mice clearly had
no visual deficits, despite their C3H background, most
likely because they were out crossed for multiple genera-
tions to the C57BL/6 line.
Assessment of locomotor activity was performed using
the Open Field test. No statistically significant differ-
ences in the number of lines crossed per trial were seen
at 12-months of age, even though 2xAD mice on the
MTNR- background crossed more lines than mice with
MTNRs. By 15-months of age these differences are
largely attenuated as was recently described for NonAD/
MTNR- mice [42].
Anxiety behavior Determination of anxiety/emotional-
ity was performed using the Elevated Plus Maze, which
incorporates both open and closed arms, the mice gener-
ally preferring the closed arms. Thus, the greater the
time spent in the open arms is considered a measure of
decreased anxiety. As seen in Fig. 2, the NonAD and
2xAD mice at 12 and at 15 months of age spent similar

























































































































Fig. 1 Behavioral assessment of sensorimotor function and activity in 12- and 15-month-old mice treated either with melatonin (MEL) or vehicle
(EtOH). The Rota-rod revealed no significant difference at any age in the length of time balance was maintained on a rotating horizontal rod that
accelerated from 4 to 40 rpm. A test of visual and motor skills in a water maze Platform Recognition test revealed no significant differences. Animals in
both groups were able to see, swim to, and climb onto the platform. Locomotor activity was assessed with an Open Field test. No significant
differences were found in control (NonAD) or 2xAD mice either with melatonin receptors (MTNR+) or without melatonin receptors (MTNR-).
All tests were evaluated with 2-way ANOVA; 12-month n = 11–14; 15-month n = 4–7; error bars represent SEM; p > 0.05
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to less anxiety (more time spent in the open arms) in
the 2xAD/MTNR- mice at 12 months of age. Addition-
ally, at 12 months of age, but even more apparent at
15 months, MEL tended to increase the time spent in
the open arms, i.e. to reduce anxiety. However, this ef-
fect was seen only in MTNR+ mice. There were no
significant group differences in the ratio of open arm en-
tries to closed arm entries.
Cognitive performance
Non-spatial cognitive: novel object recognition test
The novel object recognition test (NORT) is a facile be-
havioral assay based on the spontaneous preference of
rodents to interact more with an unfamiliar object than
with a familiar one. As such there is little to no stress on
the animal and it does not require spatial orientation. It
has been used to assess deficits in learning and memory
in various mouse models of AD [43, 44]. We tested the
effects of MEL on performance in the NORT in
15 month-old AD mice with or without their MTNRs.
As shown in Fig. 3, both groups of vehicle-treated 2×AD
mice performed poorly, i.e. showing almost equal times
exploring the novel objects and the familiar (only small
differences between the two). In contrast, the 2×AD
mice that were treated with MEL showed significantly
improved performance levels that were comparable to
the NonAD control level. These MEL effects were inde-
pendent of the presence of the MTNRs. No effects of











































Fig. 2 Determination of anxiety levels by time in spent in the open
arms of the Elevated Plus Maze. No significant differences were seen
in either the 12-month-old or in the 15-month-old NonAD control
or 2xAD mice, irrespective of the whether they possessed melatonin
receptors (MTNR+) or lacked them (MTNR-). Evaluated with 2-way
ANOVA; 12-month n = 10-13; 15-month n = 4–7; error bars represent











































Fig. 3 Measurement of non-spatial memory in 15-month-old mice
with the novel object recognition test. This test evaluates the
difference in time spent investigating a familiar versus foreign
object. The vehicle-treated 2xAD mice (clear yellow and white bars)
showed significantly poorer performance when compared to the
NonAD/MTNR+ control mice with or without MEL. This was alleviated
in the 2xAD mice that had received melatonin (MEL; striped bars),
irrespective of the presence (MTNR+) or absence (MTNR-) of melatonin
receptors. Evaluated with 2-way ANOVA; n = 4–7; error bars represent
SEM; p < 0.05
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Spatial cognitive: barnes maze and the morris water maze
Mice were tested for cognitive performance with two
standard behavioral tests for spatial/reference learning,
the Barnes Maze (circular platform test) and the Morris
Water Maze (the probe test). At 15 months of age the
2xAD/MTNR+ mice treated with MEL showed learning
in the Barnes Maze by day 8 as compared to day 1
(Fig. 4a) in contrast to EtOH-treated controls. However,
2xAD/MTNR- mice were quicker in the Barnes maze in
general, most likely due to their increased activity and
generally improved cognition as reported previously.
MEL treatment seemed to slightly potentiate this effect
even in absence of the receptors.
Comparisons of the final latencies (days 5–8 of testing)
to find the escape hole in the same mice at 12-month of
age versus their recall at 15-months of age (Fig. 4b)
revealed that vehicle-treated mice 2×AD were not able
to recall and improve their performance after three
months. In contrast, the MEL-treated 15-month-old
2×AD mice made significant improvements over their
performance at 12-months, consistent with enhanced
learning capabilities. The superior performance in the
2×AD/MTNR- mice was likely due to the consequences
of genetic deletion of the MTNRs, which gives even
NonAD/MTNR- mice a cognitive advantage over
MTNR+ mice as we recently reported [42]. In both
2xAD groups MEL treatment enabled superior perform-
ance at 15 months when compared to 12 months, al-
though in the 2xAD/MTNR- group there was only
marginal further improvement, presumably due to a
“floor effect”.
The Morris Water Maze (Fig. 5a) provides for another
assessment of spatial learning (shorter escape latencies
with training) as well as testing for working memory
(the probe test). In the case of escape latencies, clear im-
provements were seen in the NonAD/MTNR+ mice
when comparing the first and last training days (P <
0.05). Neither of the vehicle-treated 2xAD groups
showed any spatial learning. However, the 2xAD/MTNR
+ mice that received MEL had similar rates of learning
to the NonAD/MTNR+ control mice. Similar trends
were seen with the probe test, where the 2xAD mice
spent the least amount of time in the goal quadrant
(Fig. 5b) while the NonAD/MTNR+ controls spent the
most time. 2xAD/MTNR+ mice that received MEL had
performance levels comparable to the NonAD/MTNR+
controls.
Survival curve
In the early months of this study we noticed a significant
degree of mortality in the 2xAD/MTNR- mice of our
colony. A Kaplan-Meier survival plot (Fig. 6) revealed
that within the first 3–9 months of age, nearly one-third
of these animals were found dead in their cages, while
no animals of the 2xAD/MTNR+ groups died. The mor-
tality of the 2xAD/MTNR- mice was marginally, but not
significantly, affected by MEL treatment. For this reason
numerous cohorts of 2xAD/MTNR- mice had to be
combined later in our study in order to attain sufficient
animal numbers for behavioral and neuropathological
studies.
Immunohistochemistry
Long-term MEL treatment induced clear reductions in
amyloid beta deposition in 15-month-old 2xAD mice, as
indexed by Aβ burden, in both the hippocampus
(Fig. 7a-d) and the frontal cortex (Fig. 7g). NonAD
brains presented with essentially no plaques (Fig. 7e).
Quantification of Aβ plaque area (Fig. 7f,g) revealed sub-





































































































Fig. 4 Spatial learning and memory in AD mice as determined with
the Barnes Maze. a Latency to find the escape hole decreased over
8 days of testing in 15-month old 2xAD/MTNR+ mice that received
MEL, but not in MEL-treated 2xAD/MTNR- mice. b Comparison of the
average latency to escape on initial testing (days 1–4) for 12-month-
old 2xAD mice as compared to the same mice at 15 months of age
during final testing (days 5–8). Only the 2xAD/MTNR+ that received
MEL exhibited significantly improved performance. Evaluated with
2-way RM ANOVA; n = 4–7; error bars represent SEM; p < 0.05
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both 2×AD/MTNR+ and 2xAD/MTNR- mice, respect-
ively, that received MEL treatment.
ELISA for plasma Aβ peptides
Plasma levels of the amyloid peptides Aβ1–40 and Aβ1–42
were determined in cohorts of 2xAD mice at 9 months
and 14 months of age (Fig. 8). While there were no sig-
nificant differences in peptide levels between 2xAD ani-
mals possessing or lacking MTNRs, there were clear
trends for reduced Aβ levels in the MEL-treated groups.
In particular, MEL led to a significantly lowered serum
Aβ1–42 level at 14 months of age, irrespective of the
presence or absence of MTNRs.
Cytochrome C oxidase activity
Melatonin receptors slightly delay the aging-induced loss of
cytochrome c oxidase activity
Decreased cytochrome c oxidase (complex IV) activity is





















































Fig. 5 Assessment of spatial learning and memory in 15-month-old
mice using the Morris Water Maze. a Averaged escape latency in the
Morris Water maze, training day 1 versus training day 5, with four
successive trials per day. NonAD/MTNR+ vehicle treated mice (red
line) showed a significant reduction in their escape latency to the
submerged platform by day 5. MEL-treated 2xAD/MTNR+ mice (blue
line) also had significantly improved performance while none of the
other Alzheimer mice showed any significant learning. b Probe test
follow-up after Morris Water maze training as determined by
percentage of time spent in the goal quadrant. Retention of the
memory of the goal quadrant was significantly reduced in the
2xAD mice as compared to the NonAD control mice, irrespective
of the presence or absence of melatonin receptors (clear yellow
and white bars). Treatment with MEL significantly improved memory in
the 2xAD/MTNR+ (yellow, striped bar), but not in the 2xAD/MTNR- mice.
Evaluated with 2-way RM ANOVA; n = 4–7; error bars represent
SEM; p < 0.05





















Fig. 6 A Kaplan-Meier survival curve for the 2xAD mice over the course
of the study. The mice with melatonin receptors (MTNR+) suffered no
losses (n = 35), while the mice lacking melatonin receptors (MTNR-)
had increasing mortality beginning at 70 days (from n = 62 only 41
survived). MEL or vehicle treatment had no effect on survival
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complex IV activity assays on striatal extracts on
MTNR+ and MTNR- mice at 13 (Fig. 9a) and
16 months (Fig. 9b) of age. There was a striking 42 %
decline in COX activity during this time period in ex-
tracts from MTNR+ mice (p < 0.001) and a 56 % de-
cline in extracts from MTNR- mice (p < 0.001). When
MTNR- and MTNR+ mice were compared, there was a
trend for decreased complex IV activity at 13 months of
age (p = 0.14) and a significant 33 % reduction in complex
IV activity in MTNR- mice by 16 months of age (p =
0.005). For a reference point in young adult mice, we also
measured complex IV activity at 6 months of age (data
not shown). While there was no drop in complex IV activ-
ity between 6 and 13 months of age in MTNR+ mice,
there was a 34 % drop in complex IV activity during this
time in MTNR- mice (p <0.001). Therefore from 6 to
16 months of age, we found that MTNR- mice showed
33 % more loss of complex IV activity than MTNR+ mice
(67 % loss in MTNR- mice compared to 50 % loss in
MTNR+ mice). So the presence of MEL receptors slightly
delays the loss of complex IV activity with normal aging.
MEL-mediated prevention of the aging-induced loss of
complex IV activity is mostly independent of MEL receptors
As has been shown by others with aging [45] or hypoxia
[46] in rats, we found that MEL treatment completely
blocked the decline in complex IV activity from 13 to
16 months of age in both MTNR+ (p < 0.001) and
MTNR- (p < 0.001) mice (Fig. 9). Therefore, MEL treat-
ment prevents the aging-related decline in complex IV
activity through predominately receptor-independent
mechanisms, with this being especially evident between
13 and 16 months of age.
2xAD/MTNR+  (EtOH) 
NonAD/MTNR+  (EtOH) 2xAD/MTNR-  (MEL)2xAD/MTNR+  (MEL)
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Fig. 7 Immunohistochemical detection of amyloid plaques in the hippocampus of 15-month-old 2xAD mice treated with either MEL (c, d) or
vehicle (a, b). NonAD mice did not develop plaques (E). Quantitative analysis of plaque load with ImageJ revealed significant MEL effects in both
MTNR+ (p < 0.0001) and MTNR- (p = 0.0034) 2xAD hippocampi (f). Similar MEL effects were also seen in the frontal cortex (g) in both the 2xAD/
MTNR+ mice (p = 0.0001) and in the 2xAD/MTNR- mice (p = 0.0333). Evaluated with 2-way ANOVA; n = 3–4; error bars represent SEM
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AD-induced increase in complex IV activity in 16-month
mice
Several studies have shown that AβPPswe transgenic
mice are characterized by complex IV deficiency [47,
48], as amyloid-beta has been shown to reduce complex
IV activity in isolated mitochondria [49]. Unexpectedly,
in our experiments (Fig. 9) there was no decrease in
complex IV activity in 13-month 2×AD mice when com-
pared to NonAD and even an increase in complex IV ac-
tivity from 13 to 16 months of age (p = 0.01). The reason
for this unexpected finding is likely the hybrid vigor of
the outbred strain or the examination of striatum instead
of hippocampus or cerebral cortex, the brain regions
most severely effected in AD. In either case, we effect-
ively used this increased complex IV activity in the
16 month AD mice as a marker of an AD-induced mito-
chondrial stress response when examining the effects of
MEL receptor knockout and MEL treatment. Strikingly,
the unaltered complex IV activity in the 2×AD mice at
13 months of age parallels the lack of behavioral and
cognitive changes observed in these mice at 12 months
of age. Likewise, the large changes in complex IV activity
at 16 months of age correlates well with the cognitive
performance decline by 15 months of age in the 2xAD
animals.
At 13 months of age in MTNR- mice, as with MTNR+
mice, the presence of Alzheimer’s proteins did not alter
complex IV activity (2×AD/MTNR- vs. NonAD/MTNR-).
Also similar to the results observed with MTNR+ mice, a
large (45 %) increase in complex IV activity from 13 to
16 months occurred when comparing NonAD/MTNR- vs.
2×AD/MTNR- mice (p < 0.001). 2×AD/MTNR- mice had
roughly 26 % decreased complex IV activity at both
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Fig. 8 ELISA measurement of plasma Aβ1–40 and Aβ1–42 levels in 9-month-old and 14-month-old 2xAD mice. In all cases, MEL tended to lower
amyloid peptide levels. A significant effect of MEL was seen at 14 months for Aβ1–42 levels in both MTNR+ mice (p = 0.0043) and in MTNR- mice
(p = 0.011). Evaluated with 2-way ANOVA; n = 3–5; error bars represent SEM
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when compared with the aged matched 2×AD/MTNR+
controls. However, the direction and magnitude of the
change in the complex IV activity due to Alzheimer’s pro-
tein expression were similar in the 2×AD/MTNR- and
2xAD/MTNR+ mice.
Melatonin treatment reduces the high complex IV activity in
2xAD/MTNR+ mice
Surprisingly, MEL treatment greatly decreased complex
IV activity in the 2×AD/MTNR+ mice, 30 % at 13 months
(p = 0.03) and 52 % at 16 months (p < 0.001). This is the
only group where MEL treatment decreased complex IV
activity (Fig. 9). This MEL-mediated decrease in complex
IV activity in the 2×AD mice is consistent with a mechan-
ism in which there is a reactive oxygen species (ROS)-me-
diated increase in complex IV activity in 2×AD mice that
is prevented by melatonin treatment. In the 2×AD/
MTNR- mice, the complex IV activity was lower than in
2xAD/MTNR+ mice and melatonin treatment did not
have a statistically significant effect on the activity.
Antioxidant transcript analysis by qPCR
For tissues collected at 13 months, expression levels of
superoxide dismutase 1 (SOD1), glutathione peroxidase
1 (GPx-1), and catalase (CAT) were determined in the
frontal cortex by quantitative PCR. Additionally, we
measured the transcript levels of nuclear factor erythroid
2-related factor 2 (Nrf2), a transcription activator that
binds to antioxidant response elements in many genes
involved in the cellular response to oxidative stress.
Figure 10 shows that in both NonAD and 2xAD mice,
the very marked effects of MEL versus vehicle (0.1 %
ethanol) on antioxidant signaling in MTNR+ mice are
notably absent in MTNR- mice.
Discussion
Transgenic mice models for studying the cellular and
molecular basis of AD have been used for many years,
but rarely for investigations into the therapeutic poten-
tial of MEL to slow the progression of this disease [24,
50, 51]. Our 2009 publication [23], detailed the neuro-
protective effects of long-term oral MEL administration
(~0.5 mg/day) on cognitive performance, brain Aβ
levels/deposition, and antioxidant enzyme expression in
the AβPPswe/PSEN1dE9 (2xAD) mouse model. Subse-
quent recent studies continue to demonstrate that MEL
has significant and reproducible prophylactic properties
in several mouse models of AD [33, 52, 53].
Fig. 9 Complex IV activity in striatal extracts from 13- and 16-month mice. There was a decline in complex IV activity in NonAD mice and an increase
in complex IV activity in AD mice from 13 to 16 months irrespective of MEL receptor status. a At 13 months 2xAD/MTNR+ mice had higher complex IV
activity than 2xAD/MTNR- mice (p = 0.03). MEL treatment of the 2xAD/MTNR+ mice decreased complex IV activity (*p = 0.03). b At 16 months NonAD/
MTNR+ mice had higher complex IV activity than NonAD/MTNR- mice (*p = 0.005) and 2xAD/MTNR+ mice had higher complex IV activity than 2xAD/
MTNR- mice (*p = 0.02). MEL treated 16 month mice had higher complex IV activity in both NonAD/MTNR+ (*p < 0.001) and NonAD/MTNR- (*p <
0.001) groups. MEL treatment prevented the increased complex IV activity in 2xAD/MTNR+ mice (*p < 0.001). MEL treatment of NonAD/ MTNR- mice
did not restore complex IV activity to the level present in NonAD/ MTNR+ mice (*p < 0.05). Evaluated with 2-way ANOVA; error bars represent SEM
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The primary goal of the present study was to deter-
mine the role of the cognate G-protein coupled mela-
tonin receptors in mediating the neuroprotective action
of MEL in the 2xAD mouse model. As reported by the
supplier (Jackson Laboratories) the 2xAD animals begin
developing cognitive deficits after 12 months [54]. We
saw no significant cognitive deficits at 12 months of age
when using three common behavioral tests (data not
shown). However, at 15 months the picture was mark-
edly different. Using the novel object recognition test
(NORT), which assesses short-term memory in a non-
spatial task, the cognitive protection afforded the AD
mouse brain by MEL was equivalent in both the mice
with MTRs as well as in the KO mice lacking MTNRs
(Fig. 3). Whereas both vehicle-treated AD groups per-
formed poorly (i.e. they were unable to recognize nov-
elty), the MEL-treated 2xAD mice were able to perform
at the level of the non-transgenic (NonAD) vehicle-
treated control mice irrespective of whether they were
with or without the melatonin receptors. These results
are consistent with the view that MEL preserves non-
spatial cognitive performance in 2×AD mice even in the
absence of G-protein coupled membrane MTNRs.
Additional cognitive testing was conducted with the
circular platform (Barnes) test for spatial reference
learning and memory (Fig. 4). In this test, 15 month-old
2xAD mice without melatonin receptors that had re-
ceived MEL had lower latencies to the escape hole on
day 1, while the 2xAD mice with receptors learned to be
even faster over the course of the 8-day testing paradigm
when compared to vehicle-treated controls (Fig. 4a). The
day 1 differences likely reflect enhanced long-term mem-
ory in MEL-treated mice, as the same animals were
tested earlier at 12 months of age. Fig. 4b depicts com-
parative performance on the Barnes test between
12 months and 15 months of age. Significant improve-
ments with age were seen in the 2×AD mice that had re-
ceived MEL, with more pronounced improvements in
the MTNR+ mice.
Mice were also tested with the Morris Water Maze,
which includes elements of spatial learning as well as as-
sessment of working memory. As would be expected,
the NonAD/MTNR+ mice performed well in both do-
mains (Fig. 5), while the vehicle-treated 2×AD groups
performed poorly on both. Notably, cognitive perform-
ance of the 2xAD/MTNR+ mice that received MEL was
similar to the NonAD/MTNR+ control mice for both
testing components. 2×AD/MTNR- mice that received
MEL did not show neuroprotection, as their perform-
ance levels were comparable to the vehicle-treated




























































Fig. 10 Melatonin treatment effect on anti-oxidant transcript expression in frontal cortex of 13-month old mice. Melatonin significantly (p < 0.05)
lowered transcript levels for four markers of the antioxidant response system in a receptor-mediated fashion. This effect was seen in both NonAD
and 2xAD mice that possessed melatonin receptors (MTNR+), but not in mice that lacked these (MTNR-). Evaluated with 2-way ANOVA; n = 4–6;
error bars represent SEM
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2×AD/MTNR- mice. Thus, the results of these cognitive
tests confirm that MEL is capable of preserving memory
in 2×AD mice in both non-spatial and spatial domains, as
shown previously by several research groups [23, 25, 40].
Additionally, our new data reveal that MEL effects are
dependent on the MTNRs in the case of hippocampal-
dependent spatial learning tasks, such as the Barnes Maze
and the Morris Water Maze, but independent of MTNRs
for non-spatial learning.
Acute MEL administration has been reported to have
anxiolytic effects in both animal models [55, 56] and in
human trials [57, 58]. In addition, Ochoa-Sanchez and
colleagues [59] reported that the novel MT2- selective
agonist, UCM765, showed anxiolytic properties in the
Open Field test and Elevated Plus Maze. Recently, Di
Paolo et al. [60] reported that MEL had anxiolytic effects
in both NonAD and Tg2576 (AβPPswe) mice. In the
present study, we could confirm that the anxiolytic ef-
fects of MEL depended on the presence of the MTNRs
(Fig. 2). MEL trended to influence anxiety in the 2xAD
mice, but only in the presence of melatonin receptors.
For the sake of completeness we also assessed sensori-
motor function at 12 and 15 months of age in 2xAD and
control mice receiving MEL. No evidence of sensori-
motor deficits was seen on the Rota-rod or Platform
Recognition tests at any of the ages tested (Fig. 1) and
there were no statistical differences between any geno-
types or treatment groups. The slight improvements in
both tests at 15 months vs. 12 months are likely to be
due to the effects of experience. Furthermore, despite
their C3H background, these mice clearly had no visual
deficits, as was confirmed by the behavioral performance
on various tests requiring spatial learning (see Figs. 4
and 5). Evaluation of open field activity at 12 months
and at 15 months of age revealed no significant differ-
ences in any groups (Fig. 1). The slightly increased activ-
ity levels seen in the 2xAD/MTNR- mice at 12 months
is likely a consequence of genetic deletion of the
MTNRs, which we have recently demonstrated to be as-
sociated with mild hyperactivity [42].
As a neuropathological correlate of AD progression in
these animals we assessed amyloid plaque load by im-
munohistochemistry in the hippocampi and frontal cor-
tex of 15 month-old mice. A significant reduction of
plaque area was seen in MEL-treated mice as compared
to vehicle (Fig. 7), with MTNR+ mice that received MEL
having 33.5 % less plaques than controls (P < 0.001),
while MTNR- mice that received MEL having 18 % less
plaques than controls (P = 0.0034), thus comprising the
majority of the protective effect of the MEL treatment
on plaque deposition. Identical plaque loads were seen
in control 2xAD mice, indicating that the genetic dele-
tion of the melatonin receptors does not predispose the
animals to more severe neuropathology as they age.
Indeed, in our recent comprehensive characterization of
the NonAD mice [42] we demonstrated that the MTNR-
genotype slightly, but significantly, did just the opposite,
i.e. it enhanced motor performance, cognitive function
and long-term potentiation as measured in a hippocampal
slice preparation. The plaque results from the current
study (Fig. 7) confirm that the neuroprotective effects of
MEL are largely independent of melatonin receptors, al-
though maximal protection was achieved when melatonin
receptors are expressed. In other words, both receptor sig-
naling pathways as well as direct intracellular effects of
MEL appear to contribute to its plaque-inhibiting mech-
anism of action with direct, receptor-independent actions
predominating.
Although not the central focus of the current investi-
gation, it is perhaps worthy to note that the 2×AD
mouse model has been described by the commercial
supplier as having a significant degree of mortality due
to seizures in early life [61]. While we saw no evidence
of seizures for the mice expressing the melatonin recep-
tors, we did notice that the 2×AD mice without mela-
tonin receptors succumbed in significant numbers in the
first 6–9 months of life (Fig. 6). Brains from these ani-
mals showed no signs of plaque formation at 4 months
and furthermore, at the completion of the study cogni-
tion in these animals with melatonin treatment was
similarly protected as in the 2xAD/MTNR+ mice (Figs. 4
and 5). Administration of MEL to this group only mar-
ginally slowed the loss of the 2xAD/MTNR- mice. It is
not entirely clear why the genetic deletion of the mela-
tonin receptors is associated with poor early survival in
the 2×AD mice, although an alteration in the balance
between inhibitory and excitatory circuits in mice lack-
ing the melatonin receptors [42] might be a possibility
worth further testing.
The processing of the amyloid precursor protein in the
AD brain generates the pathogenic peptides, Aβ1–40 and
Aβ1–42, with the latter thought to be the major neuro-
toxic species [62, 63]. Although the blood amyloid levels
in this mouse model of AD reflect both central and per-
ipheral APP processing and clearance, we felt that as an
indirect measure of MEL’s potential to alter these activ-
ities, it would be informative to assess plasma levels of
these peptides in our 2xAD mice during the course of
plaque development. Thus, using commercial ELISAs we
determined plasma levels of Aβ1–40 and Aβ1–42 at ages 9
(cognitively presymptomatic) and 14 months (Fig. 8). At
9 months of age – when plaques are beginning to accu-
mulate – treatment of 2xAD mice with MEL led to lower
plasma levels of Aβ1–40 and Aβ1–42 in the MTNR+ mice
and a similar trend in the MTNR- mice. By 14 months of
age (by which time cognitive symptoms are fully
expressed), MEL-treated 2xAD mice of the MTNR+ geno-
type had a significant reduction in plasma Aβ1–42 as well
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as the Aβ1–42/Aβ1–40 ratio (data not shown), concomitant
with significantly lower amyloid load in the brain (Fig. 7).
In view of evidence that Aβ1–40 and Aβ1–42 may be cleared
from the brain by different mechanisms [64, 65], our over-
all results are consistent with a general reduction of amy-
loidogenic APP processing (rather than Aβ clearance) in
response to MEL administration. In agreement with this
hypothesis [25] measured hippocampal levels of Aβ1–40
and Aβ1–42 in the Tg2576 AD mouse and reported signifi-
cant reductions following treatment with MEL. Addition-
ally, this group demonstrated that MEL treatment
decreases Aβ processing via reductions of hippocampal
presenilin and β-secretase levels. More recently, Shukla et
al. 2015 reported that MEL upregulates alpha-secretase
protein levels and subsequent catalytic cleavage of beta-
APP to nonamyloidogenic products in cultured neuronal
and non-neuronal cells [66]. Thus, our current results
showing melatonin receptor-independent MEL-induced
decreases in plasma Aβ1–42 levels (Fig. 8), concomitant
with protection of non-spatial cognitive performance
(Fig. 3) and reduced amyloid plaque load following MEL
(Fig. 7) are consistent with the hypothesis that MEL’s neu-
roprotective activities are at least in part due to its long-
term effects on Aβ generation.
Brain mitochondrial function, which is very sensitive
to oxidative stress and is impaired in AD [67–69], is pro-
tected by MEL through numerous mechanisms. For ex-
ample, we reported recently that chronic MEL treatment
protected in a dose-dependent manner against Aβ-
mediated mitochondrial dysfunction at multiple levels in
2xAD mice and that this protection could be blocked by
use of specific melatonin receptor antagonists [33]. As a
further exploration of this phenomenon, we assessed the
brain activity of the mitochondrial enzyme, cytochrome
c oxidase (complex IV), in 2xAD mice possessing or
lacking MTNRs. Striatal samples were assessed, as all of
the hippocampal and cortical tissues from these animals
were used for other purposes. However, in our previous
study [47] we found that mitochondrial respiratory activ-
ity in all three of these brain regions of 2xAD mice were
similar.
Unexpectedly, we found increased complex IV activity
caused by AβPPswe/PS1 expression from 13 to 16 months
of age, not decreased expression as we and others have
observed when studying AβPPswe Alzheimer’s mice of
different genetic backgrounds [33, 70]. We have confi-
dence in our complex IV activity measurements in this
report as it is well established that there is an aging-
related decline in complex IV activity in rodent brain
[71]. This increased complex IV activity in 16-month
2xAD mouse brain may be mediated by mitochondrial
proliferation or increased expression of oxidative phos-
phorylation complex subunits in response to oxidative
stress [72, 73]. If the oxidative stress is mild or of short
duration, mitochondrial proliferation or increased ex-
pression of oxidative phosphorylation complex subunits
may increase energy reserves to maintain cellular
homeostasis, but when the oxidative stress is high or
chronic such as in AD, mitochondria become damaged
and these compensatory mechanisms become ineffective
in restoring energy levels leading to cell and tissue dys-
function. The hypothesis that the increased complex IV
activity in the 2xAD mice is caused by oxidative stress is
supported by the observation that MEL treatment of the
2xAD/MTNR+ mice completely prevented the increased
complex IV activity. MEL likely accomplishes this by
both directly scavenging ROS and by decreasing the pro-
duction of ROS from the electron transport chain [74].
Melatonin can reduce electron leakage from complexes I
and III of the ETC. This can importantly lead to reduced
formation of nitric oxide [75], peroxynitrite, and
peroxynitrite-derived free radicals such as hydroxyl radi-
cals and nitrogen dioxide, which prevent increased
NADPH oxidase and iNOS activities, with an overall ef-
fect of decreasing neural inflammation [29].
Consistent with our current findings of increased com-
plex IV activity in the 2×AD mice, another group also
found increased complex IV activity in AβPP-expressing
mice [76]. They found increased COX activity in the
ventral striatum of AβPP23 mice partially backcrossed
onto a C57BL/6 background. This report showed in-
creased complex IV activity only in specific regions of
the brain. In another report, complex IV activity in-
creased in Tg2576 mice at 5 months of age compared to
controls [77]. Another group found similar results with
these mice at 7 months of age [78]. Consistent with both
of these reports, Tg2576 mice show upregulation of
mitochondrial electron transport genes [79]. Increased
complex IV activity has also been found in neurons from
Alzheimer’s patients [80]. This increased electron trans-
port chain complex activity is consistent with the Inverse
Warburg Hypothesis of Alzheimer’s disease, which states
that aged, energetically stressed neurons attempt to up-
regulate oxidative phosphorylation to use the lactate
produced by adjacent astrocytes as a respiratory sub-
strate to maintain cellular ATP levels [81]. However, sev-
eral other groups have measured decreased complex IV
activity in various brain regions of Tg2576 mice [70, 82–
84]. In addition, reduced complex IV activity has also
been measured in double and triple transgenic mouse
models of AD combining overexpression of presenilin-1
and/or tau with mutant APP overexpression [85, 86].
A recent report has shown that the Aβ peptide directly
inhibits complex I activity of the ETC. [87]. The inhib-
ition of complex IV activity was found to be an indirect
result from damage of the mitochondrial phospholipid
cardiolipin, required for complex IV activity. Cardiolipin
was found to be oxidized as a result of the complex I
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inhibition, and not from a direct inhibition of complex
IV by Aβ as has previously been suggested [49]. Cardio-
lipin peroxidation is most frequently catalyzed by the
cardiolipin peroxidase activity of a cytochrome c-
cardiolipin complex [88]. Adding back cardiolipin to
aged mitochondria has been shown to restore complex
IV activity [43]. In addition, Aβ has been shown to de-
crease transcription of specific complex IV subunits in
certain cell types that may also contribute to the de-
creased complex IV activity [89]. In the 2xAD mice used
in this report, altered electron transport chain function
in response to increased amyloid-beta levels may have
led to decreased activity of the cardiolipin peroxidase ac-
tivity of cytochrome c, preserving or even increasing car-
diolipin levels resulting in the increased complex IV
activity measured.
Another possible reason as to why we were able to
measure increased complex IV activity in the 2xAD mice
is because we used brain extracts where increased mito-
chondrial proliferation can be detected, in contrast to
when measurements are made using isolated mitochon-
dria where increased mitochondrial proliferation is likely
missed unless paying close attention to the mass of
mitochondria isolated. It is also possible that complex
IV activity was upregulated in the 2xAD brain without
increases in mitochondrial proliferation. This could be
accomplished through expression of alternative complex
IV subunits [90] or through post-translational modifica-
tion of the complex [91]. When damaged cardiolipin
limits complex IV activity slowing the rate of electron
transport, oxygen has more time to bind the electrons
producing superoxide. Under these conditions increasing
complex IV activity would be an effective strategy to in-
crease the rate of electron transport to increase ATP
levels while also decreasing mitochondrial superoxide
production. In summary, our data show that MEL ad-
ministration protects MTNR+ mice from AD-induced
upregulation of complex IV activity. However, MEL ad-
ministration did not completely restore the increased
complex IV activity in the 2xAD/MTNR- mice suggest-
ing both receptor-dependent and independent effects are
important for protection. It is of interest to perform
similar experiments using additional brain regions and a
different genetic background of mice to determine if
these restorative effects of MEL are observed when com-
plex IV activity declines as a result of APPswe expression.
Substantial data have accumulated that link oxidative
stress to AD pathogenesis [92–94]. It is thus significant
to note that numerous studies have reported MEL ef-
fects on markers of oxidative stress [95–98]. Acutely,
MEL has been reported to elevate in many tissues the
expression of antioxidant enzymes as part of a defense
mechanism against free radicals [14, 99]. Previously, we
have shown significant effects of long-term MEL on
SOD1, GPx-1, and CAT mRNA expression in the brain
of 10-month-old 2xAD/MTNR+ mice [23]. Also, in the
present study, we evaluated antioxidant expression at
13 months of age. As seen in Fig. 10, long-term MEL
treatment was associated with lower mRNA expression
of Nrf2, SOD1, GPx-1 and CAT in the brain (frontal
cortex) of 13 month-old mice in both 2xAD and age-
matched NonAD mice. A lower expression of antioxi-
dant mechanisms is the logical outcome for brains that
have reduced levels of oxidative stress due to chronic
MEL treatment. These results are entirely consistent
with our previous study [33] demonstrating MTNR-
dependent effects of MEL in the 2xAD brain. Thus, in
view of our current data demonstrating that the effects
of MEL on some cognitive functions and on amyloid
pathogenesis in 2xAD mice are independent of MTNRs
(Figs. 3, 7, and 8), the clear implication of our current
study is that the potent effect of MEL on antioxidant
gene expression in the 2xAD brain is not the key mech-
anism for its remarkable neuroprotective capabilities.
Conclusions
Melatonin has been shown to have reproducible and sig-
nificant protective properties in a variety of neurodegen-
erative diseases. While often assumed to involve
receptor signaling through one or both of the MTNRs, a
direct test of this assumption with animals completely
lacking their MTNRs has never been reported. In the
current study with 2×AD mice we have demonstrated
that in some cognitive domains (spatial learning and
memory) MEL neuroprotection is indeed receptor-
dependent, while in others (non-spatial learning and
memory) it is receptor-independent. In addition, hippo-
campal and frontal cortical amyloid plaque loads and
plasma Aβ1–42 levels were significantly reduced by MEL
in a receptor-independent manner, while MEL reduced
cortical antioxidant gene expression in a receptor-
dependent manner. These findings demonstrate that
long term MEL significantly reduces AD neuropathology
and some associated cognitive deficits in a manner that
is independent of antioxidant pathways. Future identifi-
cation of direct molecular targets for MEL action in the




All mice were housed and handled in accordance with
Federal animal welfare guidelines and in compliance
with the Public Health Service Policy on Humane Care
and Use of Laboratory Animals (2002) and the Guide for
the Care and Use of Laboratory Animals (8th Edition).
Experiments were reviewed and approved prior to being
carried out by the Institutional Animal Use and Care
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Committee (IACUC) of the Florida State University
(Protocols #1016, 1135; Association for Assessment and
Accreditation of Laboratory Animal Care International
accreditation unit #001031; Office of Laboratory Animal
Welfare Assurance #A3854-01).
The AD double mutant transgenic mice with a
C57BL/6 x C3H background were obtained from the
Jackson Laboratory (stock # 004462), into which two
mutant transgenes were inserted at a single locus. One
transgene encodes a chimeric human/murine amyloid
beta (A4) precursor protein (AβPPswe), which was then
further modified to encode the Swedish mutations
K595N/M596L found in human. The other transgene
encodes the "DeltaE9" mutation of human presenilin 1
which is a deletion of exon 9 and corresponds to a form
of early-onset Alzheimer's disease. The AβPPswe/PS1
transgenic mouse model (2xAD) was maintained in a
hemizygous colony.
We also used a progeny of a University of Massachu-
setts Medical School mouse colony, where the melatonin
receptor knockout strains were generated by a genetic
mutation introduced by homologous recombination
[100, 101]. Briefly, sites within exon 1 of both the mela-
tonin type 1 receptor gene (MT1) and the melatonin
type 2 receptor gene (MT2) were replaced with phospho-
glycerate kinase promoter (PGK-neomycin) cassettes.
These C57BL/6 animals were then backcrossed for 10
generations to C3H/He mice because others have used
the C3H strain extensively in examining circadian be-
havioral responses to melatonin, as the C3H strain has
rhythmic melatonin production [102] unlike most other
inbred strains of mice, including the C57BL/6 [103, 104].
The resultant mice were C3B6 (C3H/He + C57BL/6)
melatonin receptor homozygous double knockout mice
(MT1
−/−/MT2
−/−), referred to here as MTNR- mice, and
their non-transgenic wild-type counterparts, referred to
here as MTNR+ mice.
The AβPPswe/PS1 heterozygous mice were outcrossed
to the melatonin receptor double knockout mice or their
non-transgenic, wild-type counterparts to obtain mice
that that either had or did not have the AβPPswe/PS1
mutations and had or did not have their melatonin re-
ceptors. Henceforth, we use the following nomenclature:
2xAD mice without their melatonin receptors are re-
ferred to as 2xAD/MTNR- and the 2xAD mice posses-
sing their two melatonin surface receptors are termed
2xAD/MTNR+. The mice without the AβPPswe/PS1 mu-
tations are termed “NonAD” and therefore, have the fol-
lowing designations: NonAD/MTNR- for the mice
without the AD mutations and without their melatonin
receptors, but NonAD/MTNR+ for mice without the
AD mutations, but possessing their melatonin receptors.
This last group is the complete wild-type, non-transgenic
control group. We then administered either melatonin
(100 μg/ml; ~0.5 mg/day; Sigma M5250) or vehicle
(0.1 % ethyl alcohol; EtOH; Electron Microscopy
Sciences 15058) in the drinking water to mice begin-
ning at 4 months of age. On the basis of a human
equivalency conversion [105] our 0.5 mg daily dose per
mouse corresponds to a daily human dose of 150 mg
(for a 75 kg individual). Melatonin stocks were made
fresh weekly in EtOH at 100 mg/ml, then diluted
1:1000 in distilled water. The water bottles were dark-
ened to prevent the melatonin from enhanced degrad-
ation due to light exposure. Multiple cohorts of the
four genotypes were treated and behaviorally tested at
12 or 15 months of age and then sacrificed for tissue
collection.
The animals were housed individually in a polycarbon-
ate cage (Ancare; 19 cm x 29 cm x 13 cm) with hard-
wood laboratory bedding chips (Nepco Beta Chip®),
nesting material (Ancare Nestlet), and a polycarbonate
mouse igloo (Bio-Serv) for enrichment. They were main-
tained under a 12 h light–dark cycle (7 am to 7 pm) at
21.1 °C and given ad libitum access to LabDiet® 5001
Rodent Chow and water.
Genotyping by PCR
At approximately 21 days of age, an IACUC and veterin-
arian recommended inhalation anesthetic, isoflurane,
(Butler Schein; 029405) was used to sedate the animal.
Once anesthetized, 2 mm terminal segment of tail was
removed with a sterile scissors. Hemostasis was achieved
using a silver nitrate applicator stick (Butler Schein;
005383) and potential pain and discomfort were allevi-
ated by applying bupivacaine hydrochloride in sterile iso-
tonic solution (Sigma B5274; 2.5 μg/ml) locally to the
excision site for long-acting pain management. Post-
surgical excision site monitoring occurred for 10 days.
The tail biopsy was placed in 250 μL of DirectPCR Tail
lysis buffer (Viagen 101-T) with 10 μL Proteinase K so-
lution (Viagen 501-K) and lysed for 6 h at 55 °C. The
sample was then incubated at 85 °C for 45 min and
briefly centrifuged. The supernatant containing the gen-
etic material was collected and stored at −20 °C for sub-
sequent PCR analysis. The resulting PCR products were
separated by gel electrophoresis on to a 1.5 % agarose
gel (EMD Millipore OmniPur® 2120-OP) for 25 min at
110 volts and subsequently imaged on a Bio-Rad Gel
Doc™ XR. Confirmation of genotypes for the MT1 −/− /
MT2 −/− double knockout (MTNR-) mice, the AβPPswe/
PSEN1dE9 (2xAD) mice and their non-transgenic
(NonAD/MTNR+) wild-type counterparts was performed.
Subsequently, RNA-Sequencing was performed on mouse
frontal cortex and hippocampal samples per previously
published protocols [106]. Sequencing was performed on
an Illumina HiSeq 2500 and confirmed that no melatonin
receptor expression was present in the MTNR- mice,
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while both MT1 and MT2 expression were clearly evident
in MTNR+ samples. The RNA-Sequencing data were con-
firmed by qPCR for both MT1 and MT2 [42]. Primers
used for genotyping are listed in Table 1.
Behavioral testing
Mice were tested in a behavioral battery, which included
open field activity, elevated plus maze, rota-rod, platform
recognition, Barnes maze, Morris water maze, Probe
test, and novel object recognition test. For all behavioral
testing, testers were blinded to the animal identification
number and their respective genotypes and were only
allowed to know the artificial 5-digit alphanumeric
scheme created to identify the animals. Behavioral tests
were performed during the 12-h dark phase, correspond-
ing to the active phase for mice, under white light condi-
tions from 7 pm to midnight. Video recording and/or
computer monitoring was utilized to provide accurate
analysis of results at a later date. Behavioral testing was
conducted with mice at either 12 months of age (2 co-
horts; n = 12–14) or at 15 months of age (1 cohort; n =
6–7). Any mice tested at 15 months of age were also
tested at 12 months of age. Animals of all genotypes
(2xAD/MTNR+, 2xAD/MTNR-, NonAD/MTNR+,
NonAD/MTNR-) and treatments (melatonin, vehicle
treated) animals were tested at the same times in the
same testing apparatus. In general, NonAD mice did
not show vehicle (EtOH) versus MEL treatment differ-
ences and are therefore not shown. Any cognitive
differences between NonAD/MTNR+ and NonAD/
MTNR- animals have already been described in our
previous publication [42].
Sensorimotor and locomotor behavior
An accelerating Rota-rod treadmill (Med Associates,
Inc., St. Albans, VT, USA) was used to assess motor and
coordination deficits. In this test, the mouse was placed
on a rotating horizontal rod, which was 3.2 cm in diam-
eter. In each trial, the animal was placed on the rod and
allowed to acclimate while the rod rotated at a constant
4 rotations per minute (rpm). Subsequently, the speed
was accelerated from 4 to 40 rpm. Latency in seconds
was recorded when either the mouse dropped to the
platform (16.5 cm) or until 5 min elapsed.
Platform Recognition is a swimming-based sensori-
motor task often used to measure the animal’s ability to
visually identify/recognize a variably placed elevated
platform, and its ability to approach and ascend on to
the surface of the platform. Specifically, this test was uti-
lized as a means of determining if any animal had visual
Table 1 Gene-specific primers used for qPCR experiments and genotyping
Gene Gene-specific Primers 5’ – 3’ GenBank# or Primer ID Amplicon Size Anneal Temp
SOD1 S: ATG GCG ATG AAA GCG GTG TG NM_011434 460 59 °C
AS: GCG CAA TCC CAA TCA CTC CA
GPx-1 S: ATG TGT GCT GCT CGG CTC TC NM_008160 590 60 °C
AS: TGC TGG GAC AGC AGG GTT TC
CAT S: AGG TTT GGC CTC ACA AGG AC NM_009804 239 58 °C
AS: GCG GTA GGG ACA GTT CAC AG
Nrf2 S: AAC GAC AGA AAC CTC CAT CTA C NM_010902 94 57 °C
AS: AGT AAG GCT TTC CAT CCT CAT C
Rp27 S: CCA GGA TAA GGA AGG AAT TCC TCC TG NM_024277 297 59 °C
AS: CCA GCA CCA CAT TCA TCA GAA GG
MT1R GAG TCC AAG TTG CTG GGC AGT GGA mMT1R-REV-WT 94 °C
GAA GTT TTC TCA GTG TCC CGC AAT GG mMT1R-FW-WT 480
CCA GCT CAT TCC TCC ACT CAT GAT CTA mMT1R-NEOFW-KO 240
MT2R CCA GGC CCC CTG TGA CTG CCC GGG mMT2R-FW-WT 68 °C
CCT GCC ACT GAG GAC AGA ACA GGG mMT2R-REV-WT 272
TGC CCC AAA GGC CTA CCC GCT TCC mMT2R-NEO-REV 550
AβPP AGG ACT GAC CAC TCG ACC AG oIMR3610 377 52 °C
CGG GGG TCT AGT TCT GCA T oIMR3611
Psen1 AAT AGA GAA CGG CAG GAG CA oIMR1644 608 54 °C
GCC ATG AGG GCA CTA ATC AT oIMR1645
Pos Ctrl CTA GGC CAC AGA ATT GAA AGA TCT oIMR7338 324 54 °C
GTA GGT GGA AAT TCT AGC ATC ATC C oIMR7339
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deficits that could impair their ability to perform in later
cognitive tests, as mice on a combined C3H background
can have retinal degeneration. The test was conducted
in a pool that measured 88 cm in diameter and 21 cm
deep and was separated into four equal quadrants by
lines suspended above the pool. The temperature of the
water was held at 26 °C. A 9 cm circular platform with a
prominent black ensign attached was raised 0.8 cm
above the surface of the water. The platform had a tex-
tured surface to aid the mouse in climbing onto the sur-
face and to encourage the mouse to stay on the
platform. A 61 cm high circular barrier was placed
around the pool to lessen the escape of the mice. The
mice were given four, 60-s maximum trials per day for
four days. On each day, the first two trials were consecu-
tive and were separated by a 30-min gap before the next
two consecutive trials were performed. The mice began
each trial facing the wall of the pool in the same quad-
rant for each trial for that particular day. The platform
was placed in a different quadrant at the start of each
day and the mice were started from a different quadrant
than the previous day. For each trial, the escape latency
was recorded in seconds, concluding when the mouse
obtained the platform. A 30-s stay on the platform be-
tween consecutive trials was encouraged. A full 60 s was
recorded for any animal that did not obtain the platform
and the mouse was gently guided towards the platform
and encouraged to remain on the platform for 30 s. Dur-
ing the 30-min gap between consecutive trials and after
daily testing, the mice were washed and placed under
warming lamps to dry. For statistical analysis, escape la-
tencies were averaged for the first two trials and the sec-
ond two trials per day.
An Open Field activity test was used to measure ex-
ploratory behavior and general activity. The mice were
individually placed into an open field box (45 cm long ×
43.9 cm wide × 30 cm high). The area was divided into a
4x4 grid (16 squares) with each square measuring
11.8 cm × 11.2 cm. Mice were given one 5-min trial in
which they were free to move around the box. Activity
was scored as the number of line crossings by the mouse
during the trial. A line crossing was defined as all four
limbs entering into a new square.
Anxiety behavior
To assess anxiety, animals were evaluated using a near-
infrared (NIR) backlit Elevated Plus Maze (EPM; Med
Associates, Inc., St. Albans, VT, USA) consisting of an
elevated plus-shaped maze with two opposite open arms
(50 cm × 10 cm) and two opposite closed arms (50 cm ×
10 cm with 40 cm walls). The tests were conducted with
NIR backlight for animal tracking. The task was initiated
by placing the test subject into the center of the maze
facing an open arm. Activity was monitored via a
mounted overhead camera and video tracking system for
a 5 min period. Entries into each arm, and the time
spent in open arms, closed arms, and center of maze
were evaluated.
Cognitive behavior
The Barnes Maze (Med Associates, Inc., St. Albans, VT,
USA) is a type of delayed match-to-place experiment
used to assess spatial/reference learning and memory.
Visual objects arranged around the maze served as
spatial cues. The maze surface was 121.8 cm in diameter
and 140.2 cm high with 40 equally spaced holes on the
periphery of the surface. A dark box filled with bedding
was positioned under one of the holes on the platform
to allow the mouse to escape from aversive stimuli. Each
mouse was assigned a specific unique escape hole for
the duration of the experiment. For each trial, the mouse
was placed in the center of the platform facing away
from its target escape hole. The aversive stimuli included
one high-intensity fan blowing at the level of the plat-
form and two 120-watt flood lamps hung from the ceil-
ing near to and aimed at the platform. Each mouse was
given one 600-s trial per day for 8 days and the escape
latency in seconds was recorded for each trial. A full
600 s was recorded for any animal that did not find its
target escape hole during a trial.
For the Morris Water Maze, the mice must adopt a
spatial learning strategy rather than a recognition strat-
egy used in the platform recognition test. All of the
equipment was set up the same as in the platform recog-
nition with a few exceptions. A circular platform without
an ensign was placed 1.5 cm below the surface of the
water, which was at 7.8 cm high. The test was run for 6
consecutive days. The platform remained in the same
quadrant for each day of the testing. During the training
phase (first 5 days) mice were given 4 successive 60 s tri-
als per day. The mice were started from a different
quadrant in each of the trials. The same quadrant start
pattern was used across the 5 days of testing. Latency to
find the platform (a maximum of 60 s) was recorded for
each trial and the four daily trials were averaged for stat-
istical analysis. If a mouse did not find the platform in
the 60 s allowed they were gently guided towards the
platform. Once a mouse was on the platform they were
allowed to sit for 30 s. If a mouse found the platform by
itself and chose to jump off a new trial began. Animals
that did not find the platform were given a latency score
of 60 s. The Probe Test was the second phase of the ex-
periment and was conducted on day 6. During this
phase, the platform was removed and the mice were
started from the quadrant opposite of the platform
quadrant. The percentage of time spent swimming in
each quadrant, including the goal quadrant (which previ-
ously held the platform) was recorded.
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The tendency of mice to interact more with a novel
object than with a familiar object has been used as a
method to study learning and memory [107]. The Novel-
Object Recognition task (NORT) was performed in a
small, opaque open field box (36 cm long by 32 cm wide
by 29 cm high). On the day before the experimental ses-
sions, animals were habituated to the experimental room
and NORT chamber for 10 min. Twenty-four hours later,
mice were given 10 min to interact in the testing cham-
ber with two-identical objects. The animal was removed
from the apparatus and given a 1-h training-to-testing
interval. One of the now familiar objects was replaced
with a novel object, which was previously tested for
comparable object manipulability and complexity inter-
actions. The mouse was again placed into the testing
chamber and allowed to interact freely with the familiar
and novel objects for 5 min. The familiar and novel ob-
jects were placed on opposite sides of the testing cham-
ber for each trial and the entire testing apparatus was
thoroughly cleaned with 70 % ethanol between each sub-
ject. The amount of time spent at both familiar and
novel objects were determined via video analysis using a
“within object area” scoring method. An animal was
scored as interacting with the object when its nose was
in contact with the object or directed at the object
within ≤ 2 cm. Time spent standing, sitting, or leaning
on the secured object was not scored as object
interaction.
Tissue collection for immunohistochemistry
All mice were euthanized by sterile intraperitoneal over-
dose injection of ketamine (Butler Schein; 100 mg/kg)
and xylazine (Vedco; 10 mg/kg) and transcardially per-
fused first by 0.9 % sterile saline, followed by 4 % para-
formaldehyde (PFA). Whole brains were removed and
placed into 15 ml of the same PFA fixative used for perfu-
sion for 24 h at 4 °C. Brains were then placed into auto-
claved 30 % sucrose solution at 4 °C until the brains sank.
They were then sectioned into 40 μm thick coronal slices
and placed into a cryoprotectant solution [108] at −20 °C
until they were examined by immunohistochemistry.
Immunohistochemistry
Brain sections were removed from the cryoprotectant
solution and washed at room temperature (RT) 3 times
for 10 min in 0.1 M phosphate-buffed saline (PBS) with
0.1 % Triton X-100 (PBSX), followed by a 15-min incu-
bation in 1 % H2O2 (prepared right before use) and then
washed an additional 3 times in PBSX. Slices were then
blocked at RT for 60 min in 1 % normal goat serum
(NGS), and incubated in PBS containing 0.4 % Triton X-
100, NGS, and rabbit anti-human amyloid-beta (Aβ; Cell
Signaling #2454) primary antibody for 18 h at 4 °C. Ini-
tial antibody titration occurred at the following dilutions:
1:1 K, 1:3 K, 1:6 K, 1:10 K, and 1:30 K after which 1:6 K
was chosen for the best signal to noise ratio. Tissues
were washed in PBSX 3 times for 10 min and treated for
2 h at RT in PBS with 0.4 % Triton X-100 and NGS with
a biotinylated goat anti-rabbit secondary antibody (Vec-
tor Laboratories, Burlingame, CA, USA) and again,
rinsed 3 times in PBSX for 10 min each. Next, they were
transferred to an avidin/biotin solution made 30 min
prior with a Vectastain Elite ABC Kit Standard (Vector
Labs) in PBS containing 0.4 % Triton X-100 for 60 min
at RT. Slices were washed twice more in 10-min PBSX
washes, followed by a 5-min rinse in sodium acetate buf-
fer (pH 7.5-7.6). Sections were processed for exactly
20 min at RT in a nickel-diaminobenzidine (Ni-DAB)
solution, prepared from previously made aliquots of
NiSO4 and DAB solution, sodium acetate, and H2O2,
followed by another 5-min sodium acetate buffer rinse.
Before the slices were mounted on slides, they had 2
final 10-min PBS rinses and allowed to dry. On the fol-
lowing day, the dehydration process included rinses for
1 min each in the following: distilled H2O; 50 % ethanol;
75 % ethanol; 95 % ethanol; 2 100 % ethanol rinses. The
slides were left to air dry for 1 min before two 5-min
washes of Histo-clear (National Diagnostics). Slides were
cover-slipped with DPX (distyrene, a plasticizer, and xy-
lene; Electron Microscopy Services, Hatfield, PA, USA)
mounting medium and examined under light micros-
copy with an Olympus MVXIO microscope. Percent
area with positive Aβ plaque load was analyzed with Fiji
(Fiji is Just ImageJ) software [109].
Blood plasma collection and ELISA for human Aβ1–40 and
Aβ1–42
Mouse blood plasma was collected for quantitative
determination of human Aβ1–40 and human Aβ1–42
peptides using a solid phase sandwich Enzyme Linked-
Immuno-Sorbent Assay (ELISA; Invitrogen Cat#
KHB3481, KHB3441). Blood collection occurred be-
tween the hours of 10 am and 1 pm. Mice were anes-
thetized with isoflurane and blood was collected via a
puncture to the vascular bed at the back of the jaw
where the orbital veins, the submandibular veins, and
the other veins draining the facial area coalesce to form
the jugular vein. The exuding droplets of blood (~0.3-
0.4 ml) were collected into an EDTA tube, after which,
a sterile gauze compress was applied to the puncture
site for 20 s. This rapid blood collection method is
more humane than retro-orbital or cardiac puncture,
leaving the animals unaffected with no signs of distress
[110]. Whole blood was centrifuged at 2000 g for 3 min
to separate the plasma, which was stored at −80 °C
until processed by ELISA according to the manufac-
turer’s protocol.
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Tissue collection for oxygen consumption assay and
transcript analysis
All mice were euthanized by sterile intraperitoneal over-
dose injection of ketamine (Butler Schein; 100 mg/kg)
and xylazine (Vedco; 10 mg/kg), followed by transcardial
0.9 % sterile saline perfusion. Brains were quickly re-
moved and placed on an ice-cold plate for dissection.
The brain was initially bisected along the sagittal plane
and the left hemisphere was dissected for hippocampus,
striatum, and frontal cortex. The dissected samples were
then flash frozen for subsequent analysis. The right
hemisphere was similarly dissected and preserved in
QIAGEN RNAlater® RNA stabilization reagent for later
mRNA analysis by qPCR.
Cytochrome C oxidase assay
Cytochrome c oxidase activity was performed using a
standard polarographic method similarly as described in
[111]. Specifically, the striatum from 13 month old mice
was dissected out, frozen, thawed, diced into cubes, and
placed into a dounce glass homogenizer along with
2.5 ml of ice cold isotonic buffer (7.5 mM sucrose, 0.1 %
BSA, 20 mM HEPES, 1 mM EGTA, 215 mM mannitol,
pH 7.2). Homogenization was performed in a dounce
tissue homogenizer using four strokes with a tight fitting
pestle and then the suspension was spun down at 13000
× g for 5 min at 4 °C. The supernatant was removed and
the pellet was resuspended in 150 μl of the ice-cold iso-
tonic buffer above with the addition of 1 mM n-dodecyl-
β-D-maltoside. Thirty-five μl of the solubilized heavy
membrane fraction was transferred into a respiratory
chamber (MT200A, Strathkelvin Instruments) contain-
ing 315 μl of buffer with 125 mM KCl, 1 μM FCCP,
50 μM cytochrome c, 2 mM ascorbate, 1 μM antimycin
A, 5 mM tetramethylphenylenediamine (TMPD), 2.5 mM
phosphate, and 20 mM HEPES, pH 7.2. The protein con-
centration in the respiratory chamber was roughly 2 mg/
mL. The rate of oxygen consumption was obtained using
a Clark oxygen electrode. After 90 s, 700 μM KCN was
added to obtain a non-cytochrome c oxidase rate of oxy-
gen consumption, which was subtracted off. The protein
concentration was determined by a BCA protein assay
(Pierce) and the respiratory rate was normalized to protein
concentration.
Isolation of mouse brain mRNA and real-time qPCR
Total cellular RNA was extracted from homogenized
frontal cortices with QIAShredder™ columns in QIA-
GEN’s buffer RLT and β-mercaptoethanol in a 100:1 ra-
tio followed by processing with the QIAGEN® RNeasy
Kit® and DNase Set treatment kits according to the man-
ufacturer’s protocols. The RNA concentration was mea-
sured with a Thermo Scientific Nanodrop photometer.
For analysis of transcript levels, one μg of total RNA was
reverse-transcribed to cDNA by means of the Bio-rad
iScriptTM reverse-transcription system. Amplification of
the cDNA was performed on a Bio-Rad CFX96 Touch™
Real-Time PCR Detection System using the iQ SYBR®
Green Supermix protocol according to the manufacturer
specifications. The following thermal cycling parameters
were used: initial heat activation of the DNA-polymerase
was performed at 95 °C for 5 min. Thereafter, 40 cycles
of 95 °C (10 s), 57–60.5 ° C (10 s) and 72 °C (30 s) were
run. The primer sequences and annealing temperatures
for the gene transcripts that were analyzed are listed in
Table 1.
Statistics
All calculations, comparisons and statistical analysis
were performed using GraphPad Prism version 6.0a soft-
ware for Mac OS X (GraphPad Software, La Jolla,
California, USA, www.graphpad.com). The values shown
on the graphs represent the means ± S.E.M. from inde-
pendent experiments. Behavioral tests comparing differ-
ences between genotypes and treatments were computed
with a 2-way ANOVA followed by Bonferroni’s multiple
comparison of means. The Kaplan-Meier survival curve
was analyzed with a Wilcoxon-Gehan-Breslow log-rank
test (chi square). Tests conducted with multiple trials or
time points were analyzed with a 2-way ANOVA for re-
peated measures and followed by the Bonferroni test for
post hoc comparison. Statistical values reaching p ≤ 0.05
were considered significant.
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